SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2184264

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2184264

Serial ESR1 Mutation Monitoring Market, By Testing Technology, By Sample Type, By Monitoring Approach, By Application, By End User, By Geography

PUBLISHED:
PAGES: 250 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4500
PDF & Excel (Multi User License - Up to 7 Users)
USD 7000
PDF & Excel (Corporate User License)
USD 10000

Add to Cart

Serial ESR1 Mutation Monitoring Market is estimated to be valued at USD 286.4 Mn in 2026 and is expected to reach USD 645.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 12.3% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 286.4 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 12.30% 2033 Value Projection: USD 645.8 Mn

The global serial ESR1 mutation monitoring market is a dedicated segment in the category of cancer screening, and liquid biopsy testing. The market is specifically centered on the identification and monitoring of ESR1 mutations in patients with HR+ HER2- advanced breast cancers, which can evolve during endocrine therapy and might result in resistance to treatment, prompting the need for serial monitoring to determine molecular changes.

Advances in circulating tumor DNA (ctDNA) testing, next-generation sequencing (NGS), digital PCR and droplet digital PCR (ddPCR) are making it easier to detect ESR1 mutations in blood tests. Growing focus on personalized oncology, early recognition of resistance, and molecularly-directed treatment selection by diagnostic laboratories, healthcare providers, and oncology stakeholders is buoying increasing interest in serial ESR1 monitoring.

Market Dynamics

The global serial ESR1 mutation monitoring market is driven by the rising need to detect endocrine therapy resistance in hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. In addition, increasing uptake of liquid biopsy and circulating tumor DNA (ctDNA) testing along with clinical validation for ESR1 mutation-guided treatment selection and progress in targeted therapies will add to the growing need for robust molecular diagnostics solution that can lead to a treatment decision in no time.

However, a number of constraints are present in the market, such as high testing costs, inconsistent assay standardization, differences in analytical sensitivity, and limited reimbursement access particularly in emerging markets. Nevertheless, significant opportunities exist in linking AI genomic analytics with greater access to liquid biopsy tests and fostering ties between pharma developers and diagnostic firms to further validate companion diagnostics and personalized cancer treatment.

Key Features of the Study

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global serial ESR1 mutation monitoring market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Guardant Health, Inc., Foundation Medicine, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., QIAGEN N.V., NeoGenomics Laboratories, Inc., Roche Diagnostics, Sysmex Corporation, Tempus AI, Inc., and GENCURIX, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global serial ESR1 mutation monitoring market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global serial ESR1 mutation monitoring market

Market Segmentation

  • Testing Technology Insights (Revenue, USD Mn, 2021 - 2033)
  • Next-Generation Sequencing (NGS)
  • PCR-Based Assays
  • Digital Droplet PCR (ddPCR)
  • Sample Type Insights (Revenue, USD Mn, 2021 - 2033)
  • Plasma
  • Serum
  • Other Blood-Derived Samples
  • Monitoring Approach Insights (Revenue, USD Mn, 2021 - 2033)
  • Baseline ESR1 Mutation Testing
  • Serial ctDNA Monitoring During Treatment
  • Testing at Disease Progression
  • Application Insights (Revenue, USD Mn, 2021 - 2033)
  • Detection of Endocrine Therapy Resistance
  • Treatment Selection and Modification
  • Monitoring of Emerging ESR1 Mutations
  • End User Insights (Revenue, USD Mn, 2021 - 2033)
  • Hospitals and Oncology Clinics
  • Diagnostic and Reference Laboratories
  • Cancer Research and Academic Institutes
  • Others
  • Regional Insights (Revenue, USD Mn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
  • Guardant Health, Inc.
  • Foundation Medicine, Inc.
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • QIAGEN N.V.
  • NeoGenomics Laboratories, Inc.
  • Roche Diagnostics
  • Sysmex Corporation
  • Tempus AI, Inc.
  • GENCURIX, Inc.
Product Code: CMI10304

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Serial ESR1 Mutation Monitoring Market, By Testing Technology
    • Global Serial ESR1 Mutation Monitoring Market, By Sample Type
    • Global Serial ESR1 Mutation Monitoring Market, By Monitoring Approach
    • Global Serial ESR1 Mutation Monitoring Market, By Application
    • Global Serial ESR1 Mutation Monitoring Market, By End User
    • Global Serial ESR1 Mutation Monitoring Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Component Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Market Opportunities
  • Industry Trends

4. Global Serial ESR1 Mutation Monitoring Market, By Testing Technology, 2021-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Next-Generation Sequencing (NGS)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • PCR-Based Assays
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Digital Droplet PCR (ddPCR)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Serial ESR1 Mutation Monitoring Market, By Sample Type, 2021-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Plasma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Serum
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Other Blood-Derived Samples
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Serial ESR1 Mutation Monitoring Market, By Monitoring Approach, 2021-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Baseline ESR1 Mutation Testing
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Serial ctDNA Monitoring During Treatment
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Testing at Disease Progression
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global Serial ESR1 Mutation Monitoring Market, By Application, 2021-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Detection of Endocrine Therapy Resistance
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Treatment Selection and Modification
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Monitoring of Emerging ESR1 Mutations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

8. Global Serial ESR1 Mutation Monitoring Market, By End User, 2021-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Hospitals and Oncology Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Diagnostic and Reference Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Cancer Research and Academic Institutes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

9. Global Serial ESR1 Mutation Monitoring Market, By Region, 2021 - 2033, Value (USD Mn)

  • Introduction
    • Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
    • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Testing Technology, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Monitoring Approach, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Testing Technology, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Monitoring Approach, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Testing Technology, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Monitoring Approach, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Testing Technology, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Monitoring Approach, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Testing Technology, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Monitoring Approach, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Testing Technology, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Monitoring Approach, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
      • South Africa
      • North Africa
      • Central Africa

10. Competitive Landscape

  • Guardant Health, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Foundation Medicine, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Thermo Fisher Scientific Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bio-Rad Laboratories, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • QIAGEN N.V.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • NeoGenomics Laboratories, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Roche Diagnostics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sysmex Corporation
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Tempus AI, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GENCURIX, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

11. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. References and Research Methodology

  • References
  • Research Methodology
  • About us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!